Amyotrophic Lateral Sclerosis (ALS)

Webinar: ALS and the National Football League

A webinar (Web-based seminar) about neurodegenerative causes of death, including amyotrophic lateral sclerosis (ALS), in retired National Football League (NFL) football players is scheduled for 1 p.m. EST, Nov. 15, 2012.

ALS: Phase 2 Clinical Trial for NP001 Shows Possible Benefit

Results from a completed phase 2 trial of the experimental therapy NP001 in people with amyotrophic lateral sclerosis (ALS) show that in some trial participants, the drug appeared to be effective at slowing or stopping progression of the disease.

ALS: SOD1 Protein Can Cause Trouble Even When It's 'Normal'

It's been known since the early 1990s that mutations in the superoxide dismutase-1 (SOD1) gene can result in the production of any number of varieties of improperly folded (misfolded) SOD1 protein, and that these misfolded proteins can cause familial amyotrophic lateral sclerosis (ALS).

White Barn


Jim received a bachelor’s degree in art from Greenville College (Ill.).  He was the art director at Regular Baptist Press in Schaumburg, Ill., prior to his retirement.  Although Jim painted for many years, he is no longer able to hold a paintbrush and work on canvases.  This piece was drawn using Photoshop CS3 from a photograph of the original barn. He has illustrated many barns and is now drawing houses using the computer.

James Johnson

Full name: 
James Johnson
James Johnson
Amyotrophic Lateral Sclerosis (ALS)
Digital Media

ALS Researcher Elected to Institute of Medicine

Don Cleveland, a longtime MDA research grantee studying amyotrophic lateral sclerosis (ALS), has been elected to the Institute of Medicine (IOM). Election to the IOM is one of the highest honors in the fields of health and medicine, and recognizes individuals who have demonstrated outstanding professional achievement and commitment to science.

Neural Stem Cell Trial in ALS ‘Very Successful’ So Far

Results from a completed phase 1 trial of neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that the stem cells and the surgical method used to transplant them were safe and well-tolerated. In addition, the experimental therapy appears to have "interrupted the progression of the disease" in some trial participants.

ALS, SMA Share a Biochemical Pathway

New evidence links the motor neuron diseases ALS (amyotrophic lateral sclerosis) and spinal muscular atrophy (SMA), an international team of scientists has reported. The researchers say the findings could lead to the identification of therapeutic targets common to both disorders.

ALS-FTD Research Briefs: P62 Gene’s Role and Screening Tool for ALS-FTD

The most visible symptom in amyotrophic lateral sclerosis (ALS) is progressive weakness and loss of muscle control due to the loss of nerve cells called motor neurons. But approximately half of all people with ALS also exhibit some symptoms of cognitive impairment and associated behavioral symptoms (frontotemporal dementia, or FTD) at some stage of their disease.

New Phase 2b Trial of Tirasemtiv (CK-2017357) in ALS

Update (Oct. 29, 2012): This article has been updated to reflect the fact that the trial is now open to recruitment.